Health Canada Orders Parkinson Drug Associated With Heart Problem Off Market
Posted on: Thursday, 16 August 2007, 15:23 CDT
TORONTO (CP) - Health Canada is ordering a drug used for treatment of Parkinson's disease off the market.
The department has told maker Eli Lilly that sales of the drug Permax (pergolide mesylate) must cease as of Aug. 30. Studies have shown the drug can cause serious heart valve damage in some users.
Eli Lilly voluntarily withdrew the drug from the U.S. market in late March after studies in the New England Journal of Medicine underscored the valve problem risk.
Health Canada says there are alternatives to Permax available to people with Parkinson's disease.
It suggests patients on the drug should be gradually weaned off it under the care of their doctors.
Permax is the subject of several class action suits filed by people who claim the drug triggered compulsive behaviours like uncontrollable gambling.
Source: Canadian Press
Related Articles
- Eli Lilly Parkinson's Drug Removed From Market
- Parkinson's Drugs May Have More Risks
- Sex and Gambling Link to Parkinson's Drug
- The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education
- Parkinson's drugs may cause sudden sleepiness
- Parkinson's Drugs Cause Uncontrollable Sleepiness
- WHO Programme for International Drug Monitoring
- Abnormal Drug Response: Opportunities for Risk Reduction Through Pharmacogenetics
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
 |
 |
User Comments (0)
RSS Feeds